KLOW is sold as a skin, repair and recovery blend, and search results now answer "what are its benefits" mostly from med-spa pages. This page takes each skin benefit those pages claim and traces it to the study behind it. It reports, it does not recommend. It carries no dose and no route, and the dosage reporting for the blend lives on Peptifact's KLOW dosage page.
The short version: the human skin figures come from topical products, not from anything injected, and the one ingredient that makes KLOW different from GLOW has no human data at all.
What KLOW is, in one paragraph
On the sellers' labels that state a split, a KLOW vial holds GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. That is the three-peptide formula set out on our glow blend composition page, with 10 mg of KPV added. Peptide Lexicon's KLOW entry weighs and counts the vial and finds GHK-Cu at 72% of the molecules. For the benefits question, the useful point is simple: KLOW and GLOW deliver the same amounts of three of their four ingredients, so any benefit that belongs to KLOW alone has to come from KPV.
The benefits as clinics state them
A Chicago med spa's KLOW treatment page, last modified 19 August 2026, is typical. It describes the protocol as "designed to support tissue repair, reduce inflammation, rebuild collagen, and promote gut healing". It assigns a role to each ingredient: "GHK-Cu stimulates collagen and elastin production", and BPC-157 and TB-500 "handle the acute repair work". To its credit the same page says none of the four is FDA-approved and that "human clinical data for KPV specifically is limited".
It also quotes numbers, and the numbers are where the trail becomes checkable. They are the right numbers from the wrong products.
Claim by claim, to the study behind it
| Claim on the clinic page | What the study behind it tested | Route in that study |
|---|---|---|
| GHK-Cu gives "a 55.8% reduction in wrinkle volume and a 32.8% reduction in wrinkle depth" over 8 weeks | 40 women aged 40–65, GHK-Cu in a lipid nano-carrier serum, twice daily for 8 weeks, against a control serum (Badenhorst 2016) | Topical face serum |
| Thymosin beta-4 "studied in Phase II clinical trials for corneal wound healing" | Eye drops of the full 43-amino-acid protein | Topical ophthalmic |
| BPC-157 relief in knee pain, 7 of 12 patients | A 12-patient knee-pain pilot, in the clinic's own description | A single injection, for joint pain, with no skin endpoint |
| KPV "significantly reduces gut inflammation" | Colitis in animals | Not a human study |
Put side by side, the pattern is plain. The human results on skin belong to creams, gels and drops. They say nothing about what the same molecule does after injection, and none of them tested the ingredients together.
The census, per ingredient, for skin
Every count below was run on 23 September 2026 with PubMed's valid "randomized controlled trial"[pt] filter. As a control, the same filter returned 2,308 records for retinol, so a zero here is a real zero. Every non-zero was opened and read before it was counted.
| Ingredient | Randomized human records on skin | What those records are |
|---|---|---|
| GHK-Cu (every synonym: GHK-Cu, copper tripeptide-1, GHK copper, glycyl-histidyl-lysine, copper peptide) | 1 | Two hits. One is a rabbit wound study in a veterinary journal. The other, Miller 2006, is 13 people after CO2 laser resurfacing, and it found no objective difference in redness, wrinkles or skin quality, only higher patient satisfaction (p = .04) |
| TB-500 / thymosin beta-4 | 2 | Both are reports of one European trial of topical thymosin beta-4 on venous leg ulcers. It tested the full protein, not the 7-residue fragment sold as TB-500 |
| BPC-157 | 0 | 89 records mention skin, wounds or burns. None is a randomized human trial |
| KPV (KPV, Lys-Pro-Val, lysyl-prolyl-valine) | 0 | The filter returned five hits, and all five were abbreviation collisions: an IVF trial, a neonatal trial, an airway study. None was about the peptide |
The Badenhorst study is missing from this table because it does not appear in PubMed. It was published in the Journal of Aging Science, which PubMed does not index. That is not a mark against the study. It does mean the figure clinics quote most often cannot be found with the search a careful reader would run first.
ClinicalTrials.gov tells the same story. GHK-Cu's three registrations are a topical gel on skin wounds (recruiting), an adhesive patch that measures GHK in the blood, and a facial-device study. Thymosin beta-4's skin trials, for pressure ulcers and for epidermolysis bullosa, tested the protein as a topical gel. The epidermolysis bullosa trial was stopped for "lack of patient availability and expiration of study drug".
What adding KPV changes
KPV is the last three amino acids of alpha-melanocyte-stimulating hormone. On 23 September 2026 its skin literature was 34 PubMed records. They are cell-culture and animal work, plus one delivery study that pushed KPV through microporated human skin in a laboratory (Pawar 2017). No human skin trial exists, and the ClinicalTrials.gov search for "KPV" returned zero records.
FDA has put the gap in its own words. Its page on bulk substances that may present significant safety risks in compounding, current as of 22 April 2026, says: "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration." The same page lists injectable GHK-Cu and the TB-500 fragment for possible immunogenicity from aggregation and peptide-related impurities.
So for skin, the case that KLOW does more than GLOW rests entirely on an ingredient that has never been given to a person in a registered study.
The timelines
A search for how long KLOW takes returns confident windows: two to three weeks for early changes, six to twelve for visible ones. We found no source for either. The only eight-week figure in this literature is the length of the topical GHK-Cu serum study, and a follow-up period is not a measurement of how long an injected blend takes. Photographs have the same limit, as our glow peptide before-and-after page sets out.
What would change this page
A registered trial of the blend with a skin endpoint. A human trial of KPV on any route. A comparison of injected and topical GHK-Cu on the same measure. Any one of these would be reported here, dated. For the three-peptide version and the component evidence in more depth, see our glow stack guide. For topical copper peptides, which is where the human skin data actually is, see the copper peptides guide.
Sources
- Better Med Spa, "KLOW Protocol Peptide Therapy Chicago", bettermedspa.com, page modified 2026-08-19, read 2026-09-23.
- Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science 2016. ResearchGate record. Not indexed in PubMed.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006;8(4):252-9. PMID 16847171.
- Cangul IT, et al. Topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol 2006. PMID 17083573.
- Guarnera G, et al. Thymosin beta-4 and venous ulcers: a European prospective, randomized study. Ann N Y Acad Sci 2007. PMID 17495250; and 2010, PMID 20536470.
- Pawar K, et al. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci 2017. PMID 28343991.
- ClinicalTrials.gov: NCT00382174 (thymosin beta-4 gel, pressure ulcers, 72 enrolled, results posted), NCT00311766 (epidermolysis bullosa, terminated), NCT07437586 (topical GHK-Cu gel, recruiting). Searches for KLOW, KPV, GHK-Cu, BPC-157 and thymosin beta 4 run 2026-09-23.
- PubMed E-utilities searches as described in the census table, run 2026-09-23, with the retinol control.
- U.S. FDA, "Certain bulk drug substances for use in compounding that may present significant safety risks", fda.gov, content current as of 2026-04-22, read 2026-09-23.